Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...

B. Riley reduced their Q1 2025 earnings per share estimates for shares of Onsemi in a report released on Friday, January 24th ...

B. Riley analyst Zach Cummins downgraded Logility (LGTY) to Neutral from Buy with a $14.30 price target after Aptean, Insight Partners, ...

The recent decline in Foghorn Therapeutics' stock was attributed to the discontinuation of another of its products, FHD-286. However, the analysts emphasized that this event does not impact their ...

Redwire Corp (NYSE:RDW) was upgraded to Buy from Neutral at financial services company B. Riley, which also hiked its price target on the space infrastructure provider to $27.00 from $9.50.

President Donald Trump plans to sign the Laken Riley Act into law as his administration's first piece of legislation.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.13% of ...

Ahead of Trump's signing, Laken Riley's mother, Allyson Phillips, spoke to those in the room. Phillips began by thanking ...